Article

Prediabetes Linked to Increased Risk of Myocardial Infarction

An analysis of the National Inpatient Sample at ENDO 2022 provides insight into the risk of myocardial infarction associated with prediabetes compared against normoglycemic patients.

Geethika Thota, MD

Geethika Thota, MD

New research presented at the Endocrine Society’s annual meeting outlines the intrinsic risk of myocardial infarction associated with prediabetes.

An analysis of data from the National Inpatient Sample (NIS) performed by investigators at Saint Peter’s University Hospital and Rutgers Robert Wood Johnson Medical School, results of the study shed light on the association of diabetes with myocardial infarction, demonstrating the association is evident with prediabetes and not just type 2 diabetes.

“Our study serves as a wake-up to everyone to shift the focus to managing prediabetes, not just diabetes,” said lead investigator Geethika Thota, MD, an internal medicine resident with Saint Peter’s Healthcare System, in a statement from the Endocrine Society. “Based on our findings, we encourage everyone to make lifestyle changes, follow a healthy diet and regularly exercise for at least 150 minutes each week in patients with prediabetes to decrease the risk of heart attacks.”

Although the growing number of patients with type 2 diabetes has dominated the media landscape in recent years, the epidemic of prediabetes has grown in stride, but received less attention from both mainstream media outlets and as a research priority. As more data has emerged regarding the cardiovascular risk associated with prediabetes, a possible association between prediabetes and risk of myocardial infarction has risen as a research interest.

For more on cardiovascular risk in patients with diabetes and prediabetes, check out our cardiology resource center!

Thota and colleagues designed the current study as an analysis of data from the NIS. Using the NIS from 2016-2018, investigators identified a cohort of 1,794,149 (95% CI, 1,753,742-1,834,556) weighted hospitalizations with a primary or secondary diagnosis of myocardial infarction for inclusion in their analyses. For the purpose of analysis, investigators created 3 separate multivariate logistic regression models with myocardial infarction, percutaneous coronary intervention, and coronary artery bypass grafting used as the outcomes of interest.

Initial analysis indicated prediabetes was associated with an increased likelihood of experiencing myocardial infarction (OR, 1.41 [95% CI, 1.35-1.47]; P=.0001). In analyses adjusted for age, sex, race, family history of myocardial infarction, dyslipidemia, hypertension, diabetes nicotine dependence, and obesity, results suggested pore diabetes was significantly associated with increased likelihood of myocardial infarction (OR, 1.25 [95% CI 1.20-1.31]; P=0.001), percutaneous coronary intervention (OR, 1.45 [95% CI 1.37-1.53]; P=0.001) and CABG (OR 1.95, [95% CI 1.77-2.16]; P=0.001).

“Our findings reinforce the importance of early recognition by screening and early intervention of prediabetes by lifestyle changes and/or medications to decrease the risk of cardiovascular events,” Thota added.

This study, “Prediabetes is a Risk Factor for Myocardial Infarction-A National Inpatient Sample Study,” was presented at ENDO 2022.

Related Videos
Diabetes Dialogue: Diabetes Tech Updates from November 2024 | Image Credit: HCPLive
The APAC Recap: Cardiomyopathy at CAPP Live 2024 with Greg Duck, PA-C | Image Credit: APAC
The APAC Recap: Peripheral Artery Disease at CAPP Live 2024 with Bob Ross, PA-C | Image Credit: APAC
AMG0001 Advances Healing in CLTI with David G. Armstrong, DPM, PhD, and Michael S. Conte, MD | Image Credit: Canva
Brigit Vogel, MD: Exploring Geographical Disparities in PAD Care Across US| Image Credit: LinkedIn
| Image Credit: X
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Stephen Nicholls, MBBS, PhD | Credit: Monash University
Marianna Fontana, MD, PhD: Nex-Z Shows Promise in ATTR-CM Phase 1 Trial | Image Credit: Radcliffe Cardiology
© 2024 MJH Life Sciences

All rights reserved.